The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
Prostate cancer (PC) is one of the leading causes of cancer death in the male population. Currently, the pathogenesis of prostate cancer has been studied in sufficient detail, which makes a successful radical treatment possible in most cases. However, in about 30% of patients traditional methods (e....
Main Authors: | А. А. Gritskevich, I. G. Rusakov, Т. Р. Baitman, S. V. Mishugin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-06-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/6210 |
Similar Items
-
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01) -
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01) -
POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01) -
PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
by: Ciara S. McNevin, et al.
Published: (2022-09-01) -
The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)